TITLE

THROMBOLYTIC THERAPY

AUTHOR(S)
Loewe, Leo; Halpern, Alfred
PUB. DATE
May 1961
SOURCE
Angiology;May1961, Vol. 12 Issue 5, p147
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
Discusses the fibrinolytic treatment of thromboembolic disease. Potential of fibrinolysin, a fibrinolytic agent to dissolve thrombi within the circulation; Capacity to dissolve the fibrin binding the clot without affecting the other proteins in the blood producing adverse reactions; Influence of the agent in increasing the incidence of side effects.
ACCESSION #
16430328

 

Related Articles

  • FIBRINOLYSIN THERAPY IN THROMBOEMBOLIC DISEASE. Randolph, W. Alan; Starling, Howard M. // Angiology;May1961, Vol. 12 Issue 5, p179 

    Reports on the aid of fibrinolysin therapy in thromboembolic disease. Toxicity of the agent as indicated by the relatively small number of toxic responses; Indication of a negative hemorrhagic complications caused by the drug; Demonstration of drug efficacy in the drug.

  • AN OPHTHALMOLOGIST'S APPROACH TO FIBRINOLYSIS. Drance, S. M. // Angiology;May1961, Vol. 12 Issue 5, p149 

    Focuses on the efficacy of antifibrinolytic agent fibrinolysin in the treatment of central retinal artery occlusion. Dissolution of intravascular clots occurring as a result of trauma; Developments observed in a patient injected with large doses of the drug followed by anticoagulant therapy;...

  • Early thrombin generation and impaired fibrinolysis after SCT associate with acute GVHD. Pinomäki, A.; Volin, L.; Joutsi-Korhonen, L.; Virtanen, J. O.; Lemponen, M.; Ruutu, T.; Lassila, R. // Bone Marrow Transplantation;Apr2010, Vol. 45 Issue 4, p730 

    The evolution of coagulation and fibrinolysis has not been thoroughly evaluated in allogeneic SCT. In this pilot study, we characterized the adaptive mechanisms of coagulation and fibrinolysis during allogeneic SCT and 3-month follow-up and studied possible associations with outcome, including...

  • Development of New Fibrinolytic Agents. Ueshima, Shigeru; Matsuo, Osamu // Current Pharmaceutical Design;Mar2006, Vol. 12 Issue 7, p849 

    Since the activation of coagulation system and platelets triggers the thrombosis, the agents possessing anticoagulation or anti-platelet function have been used for the antithrombotic procession actions. However, in the physiological condition, the fibrinolytic system serves as antithrombotic,...

  • Early use of intrapleural fibrinolytics in the management of postpneumonic empyema. A prospective study. Misthos, Panagiotis; Sepsas, Evangelos; Konstantinou, Marios; Athanassiadi, Kalliopi; Skottis, Ioannis; Lioulias, Achilles // European Journal of Cardio-Thoracic Surgery;Oct2005, Vol. 28 Issue 4, p599 

    Abstract: Objective: A prospective randomized study was conducted in order to analyze the role of fibrinolytics in the treatment of complicated parapneumonic effusion. Methods: From 2001 to 2004, 127 consecutive patients were managed for thoracic empyema. In all cases the cause was bacterial...

  • Eptacog-alfa: most thromboembolic AEs from unlabelled use.  // Reactions Weekly;1/28/2006, Issue 1086, p5 

    Discusses research on thromboembolic adverse events following administration of eptacog-alfa, a recombinant human coagulation factor VIIa. Reference to a study by K. A. O'Connell et al, published in the January 18, 2006 issue of the "Journal of the American Medical Association"; Review of data...

  • BOX 11-7 DISSOLVING CLOTS. Scanlon, Valerie C.; Sanders, Tina // Essentials of Anatomy & Physiology;Jan2007, p268 

    Information on dissolving clots from Chapter 11 of the book "Essentials of Anatomy & Physiology" is presented. It identifies arteries, vessels and veins that might be affected by abnormal blood clots. It offers information on streptokinase, a bacterial toxin used to dissolve blood clots, and its...

  • FIBRINOLYSIN THERAPY OF THROMBOEMBOLISM: THREE YEARS' EXPERIENCE. Sheffer, Albert L.; Lisker, Samuel; Nemir Jr., Paul // Angiology;May1961, Vol. 12 Issue 5, p165 

    The clinical evaluation of 67 patients treated with fibrinolysin is presented. Thirty-three cases reported previously are added for follow-up purposes. Thrombophlebitis, pulmonary embolism, vascular surgery and ophthalmologic experience are described. There are a few encouraging examples in each...

  • Changes in clot lysis levels of reteplase and streptokinase following continuous wave ultrasound exposure, at ultrasound intensities following attenuation from the skull bone. Härdig, Bjarne; Carlson, Jonas; Roijer, Anders // BMC Cardiovascular Disorders;2008, Vol. 8, Special section p1 

    Background: Ultrasound (US) has been used to enhance thrombolytic therapy in the treatment of stroke. Considerable attenuation of US intensity is however noted if US is applied over the temporal bone. The aim of this study was therefore to explore possible changes in the effect of thrombolytic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics